Talzenna (talazoparib)

General Description:

Talzenna (talazoparib) is an oral PARP inhibitor used to treat adult patients with HER2-negative locally advanced or metastatic breast cancer who have a germline BRCA mutation (gBRCA).

Getting Talzenna (talazoparib) in India

Talzenna (talazoparib)is approved in the U.S., Europe, and other countries but it is not yet sold in India commercially. Still, patients in India can get this important medicine for their treatment through a special program called the Named Patient Program (NPP).

MitoGENE helps eligible patients get Talzenna (talazoparib) legally and safely, with the support of their treating physician. We take care of all the necessary paperwork, import process, and delivery—while making sure everything follows Indian regulations.

If you or someone you care about requireTalzenna (talazoparib), MitoGENE is here to guide and support you every step of the way.

Disease Indications: HER2-negative metastatic or locally advanced breast cancer with BRCA mutation

Manufacturer:Pfizer Inc.

Usage:Oral

Medicine Approved by:

• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Therapeutic Goods Administration (TGA)

Available Dosage Form & Package:

• 1 mg capsule – blister pack of 30

Shipping:

Room Temperature Shipping. This medication is shipped using standard delivery methods, ensuring it remains within a controlled room temperature range of 15°C to 25°C throughout transit.